Concurrent chemoradiotherapy for stage III non-small cell lung cancer: correct clinical management as the basis to move beyond

Lung cancer (LC) is the most common type of cancer and the principal cause of death from cancer worldwide. In 2018, data from Globocan estimated over 2.1 millions new cases of LC were reported, with 1.8 million deaths globally (1). Smoking is main cause of LC, and almost 85–90% of patients with LC are or were smokers (2). Smokers have 20–30 times more risk to developed LC (3).